ARGX

707.4

+1.61%↑

SHL.DE

35.43

+2.22%↑

FRE

37.72

-1%↓

PHIA

23.25

-1.19%↓

FME

37.47

-0.5%↓

ARGX

707.4

+1.61%↑

SHL.DE

35.43

+2.22%↑

FRE

37.72

-1%↓

PHIA

23.25

-1.19%↓

FME

37.47

-0.5%↓

ARGX

707.4

+1.61%↑

SHL.DE

35.43

+2.22%↑

FRE

37.72

-1%↓

PHIA

23.25

-1.19%↓

FME

37.47

-0.5%↓

ARGX

707.4

+1.61%↑

SHL.DE

35.43

+2.22%↑

FRE

37.72

-1%↓

PHIA

23.25

-1.19%↓

FME

37.47

-0.5%↓

ARGX

707.4

+1.61%↑

SHL.DE

35.43

+2.22%↑

FRE

37.72

-1%↓

PHIA

23.25

-1.19%↓

FME

37.47

-0.5%↓

Home・Lista de Ações・Sanofi SA
Search

Sanofi SA

Abrir

SetorSaúde

76.6 -0.42

Comprar

Atualização de preço 27 de mai. de 2026, 09:46 UTC

ComprarVender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

76.01

Máximo

76.96

Indicadores-chave

By Trading Economics

Rendimento

-394M

1.6B

Vendas

-12B

11B

P/E

Médio do Setor

19.273

50.102

EPS

1.34

Margem de lucro

14.354

Funcionários

74,846

EBITDA

1.5B

2.7B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+22.93% upside

Dividendos

By Dow Jones

Próximos Ganhos

30 de jul. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-7.5B

91B

Abertura anterior

77.02

Fecho anterior

76.6

Sentimento de Notícias

By Acuity

39%

61%

113 / 344 Ranking em Healthcare

Sanofi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de abr. de 2026, 09:03 UTC

Ganhos

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

DJ

Ler

29 de abr. de 2026, 05:27 UTC

Ganhos

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

DJ

Ler

23 de abr. de 2026, 06:12 UTC

Ganhos

Sanofi Posts Higher Sales Amid Leadership Transition

DJ

Ler

7 de mai. de 2026, 06:47 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

DJ

Ler

1 de mai. de 2026, 06:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

DJ

Ler

1 de mai. de 2026, 06:13 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

DJ

Ler

1 de mai. de 2026, 06:12 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK Financed Deal From Existing Cash Resources

DJ

Ler

1 de mai. de 2026, 06:08 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK Announced Key Terms of Deal July 2025

DJ

Ler

1 de mai. de 2026, 06:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK Buys TSB Banking for GBP2.65B

DJ

Ler

1 de mai. de 2026, 06:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Santander UK Buys TSB Banking Group

DJ

Ler

29 de abr. de 2026, 12:01 UTC

Ganhos

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

DJ

Ler

29 de abr. de 2026, 06:27 UTC

Conversa de Mercado
Ganhos

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

DJ

Ler

29 de abr. de 2026, 04:55 UTC

Ganhos

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

DJ

Ler

29 de abr. de 2026, 04:55 UTC

Ganhos

Santander 1Q Loan Loss Provisions EUR3.225B

DJ

Ler

29 de abr. de 2026, 04:54 UTC

Ganhos

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

DJ

Ler

29 de abr. de 2026, 04:54 UTC

Ganhos

Santander 1Q Operating Expenses EUR6.48B

DJ

Ler

29 de abr. de 2026, 04:52 UTC

Ganhos

Santander Backs 2028 View

DJ

Ler

29 de abr. de 2026, 04:52 UTC

Ganhos

Santander Backs 2026 View

DJ

Ler

29 de abr. de 2026, 04:52 UTC

Ganhos

Santander 1Q Underlying RoTE 15.2%

DJ

Ler

29 de abr. de 2026, 04:51 UTC

Ganhos

Santander End-1Q CET1 Ratio 14.4%

DJ

Ler

29 de abr. de 2026, 04:51 UTC

Ganhos

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

DJ

Ler

29 de abr. de 2026, 04:51 UTC

Ganhos

Santander 1Q Net Interest Income EUR11.02B

DJ

Ler

29 de abr. de 2026, 04:50 UTC

Ganhos

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

DJ

Ler

29 de abr. de 2026, 04:50 UTC

Ganhos

Santander 1Q Underlying Pft EUR3.56B

DJ

Ler

29 de abr. de 2026, 04:49 UTC

Ganhos

Santander 1Q Net Pft EUR5.455B

DJ

Ler

29 de abr. de 2026, 04:49 UTC

Ganhos

Analysts Saw Santander 1Q Rev EUR15.00B

DJ

Ler

29 de abr. de 2026, 04:49 UTC

Ganhos

Santander 1Q Rev EUR15.14B

DJ

Ler

27 de abr. de 2026, 09:32 UTC

Conversa de Mercado
Ganhos

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

DJ

Ler

27 de abr. de 2026, 09:19 UTC

Conversa de Mercado

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

DJ

Ler

23 de abr. de 2026, 05:34 UTC

Ganhos

Sanofi: 2026 Expectations Are at Constant Exchange Rates

DJ

Ler

Comparação entre Pares

Variação de preço

Sanofi SA Previsão

Preço-alvo

By TipRanks

22.93% parte superior

Previsão para 12 meses

Média 95.219 EUR  22.93%

Máximo 107 EUR

Mínimo 85 EUR

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Sanofi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

9 ratings

4

Comprar

5

Manter

0

Vender

Com base em 9 analistas que deram avaliações de ações para Sanofi SA - Dist nos últimos 3 meses.

Sentimento

By Acuity

113 / 344 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Outras ações do setor

ARGX

Argenx SE

707.4

↑ +1.61%

SHL.DE

Siemens Healthineers AG

35.43

↑ +2.22%

FRE

Fresenius SE & Co KGaA

37.72

↓-1%

PHIA

Koninklijke Philips NV

23.25

↓-1.19%

FME

Fresenius Medical Care AG

37.47

↓-0.5%
help-icon Live chat